In the quiet persistence of a single researcher's decades-long question — why do some infants with the same genetic mutation suffer while others do not — science has uncovered a previously unknown mechanism by which cells dispose of their most dangerous debris. Richard Sifers of Baylor College of Medicine, studying the rare liver disease alpha1-antitrypsin deficiency, found that an enzyme called Man1b1 operates as both a known and an entirely novel quality-control agent, tagging misfolded proteins for destruction through two distinct pathways. What began as a mystery written in the livers of s
Rare liver disease study reveals novel protein disposal mechanism with broader disease implications
Infants with severe AAT deficiency-associated liver disease require transplantation to survive, with only 17% of carriers developing clinically significant disease.
A rare disease in infants illuminated a pathway that could prevent common neurological disorders in old age.
Mark
Why did it take thirty years to understand what was happening in these infants' livers?
Mimi
Because the variation itself was the puzzle. You could see that some babies got sick and some didn't, but you couldn't see why. Sifers had to build the tools first—the screening test—before he could even ask the right questions about the mechanism.
Mark
So the Man1b1 enzyme is like a janitor in the cell?
Mimi
More like a quality inspector who also runs the incinerator. It checks the protein, marks it for disposal, and then—as they discovered later—it can also break down the garbage that's already piled up. It has two completely different jobs on two different parts of itself.
Mark
If only 17 percent of babies with the Z mutation get sick, why focus on the ones who do?
Mimi
Because those sick babies are telling you something about the system. They're the ones where something went wrong. If you understand why they fail, you understand what the system needs to work properly.
Mark
Does this mean we could treat Alzheimer's by boosting Man1b1?
Mimi
That's the hope, but it's much earlier than that. They've shown the pathway exists and matters. Whether you can safely target it without causing other problems—that's the next phase of work.
Mark
Why does a liver disease in infants matter for brain disease in the elderly?
Mimi
Because the underlying problem is the same: misfolded proteins accumulating where they shouldn't. The liver just shows you the answer faster. Babies with the genetic variant fail in months. In Alzheimer's, the same process takes decades.
O Pulso
- Some infants carrying the AAT-Z mutation face life-threatening liver failure while others with identical genetics remain unharmed — a disparity that demanded explanation for thirty years.
- A genetic variant that reduces levels of the Man1b1 cleanup enzyme tips the balance, allowing misfolded proteins to accumulate faster than the liver can clear them and triggering organ failure in infancy.
- Researchers mapped the cellular disposal route — from the endoplasmic reticulum to the proteasome — and identified Man1b1 as the critical enzyme that marks defective proteins for destruction.
- A second, entirely undescribed function of Man1b1 was discovered operating from the opposite end of the enzyme, suggesting a parallel disposal pathway no one had previously observed.
- The newly identified mechanism may target the soluble protein aggregates implicated in Alzheimer's disease, intellectual disability disorders, and HIV infection, transforming a rare pediatric finding into a broad therapeutic frontier.
In the quiet persistence of a single researcher's decades-long question — why do some infants with the same genetic mutation suffer while others do not — science has uncovered a previously unknown mechanism by which cells dispose of their most dangerous debris. Richard Sifers of Baylor College of Medicine, studying the rare liver disease alpha1-antitrypsin deficiency, found that an enzyme called Man1b1 operates as both a known and an entirely novel quality-control agent, tagging misfolded proteins for destruction through two distinct pathways. What began as a mystery written in the livers of sick infants now opens a corridor toward understanding Alzheimer's disease and other conditions where the body's protein-disposal systems quietly fail.
Three decades ago, pathologist Richard Sifers noticed a troubling inconsistency: some infants carrying the same genetic mutation in the alpha1-antitrypsin gene developed fatal liver disease and required transplants, while others with identical mutations never fell seriously ill. Only 17 percent of newborns carrying two copies of the Z mutation develop clinically significant liver disease, and fewer than 3 percent reach life-threatening failure in infancy. The question of why haunted Sifers throughout his career at Baylor College of Medicine.
Alpha1-antitrypsin is a liver-produced protein that travels through the bloodstream to protect the lungs. The Z mutation produces a defective version that cannot fold properly, leaving it trapped in liver cells where it accumulates like refuse with nowhere to go. Sifers developed a screening test to identify at-risk newborns, but predicting illness was not the same as understanding it. He and his colleagues began mapping the cell's disposal system — the route by which misfolded proteins travel from the endoplasmic reticulum to proteasomes in the cytosol, where they are broken down. At the center of this process, they found an enzyme called Man1b1, which strips sugar molecules from defective proteins and marks them for destruction.
Studying liver tissue from transplanted infants, the team identified a genetic variant that reduced Man1b1 expression. Babies carrying both the AAT-Z mutation and this variant had less of the cleanup enzyme available, causing misfolded proteins to accumulate faster and pushing the liver past its threshold for damage. The mystery of infant susceptibility was solved.
But the investigation yielded something unexpected. Further study revealed that Man1b1 performs a second, entirely novel function through its N-terminal domain — a mechanism distinct from its known role and potentially capable of eliminating the soluble protein aggregates associated with conformational diseases like Alzheimer's, intellectual disability disorders, and HIV infection. A pathway uncovered in the livers of sick infants may ultimately point toward treatments for some of the most common and devastating neurological conditions of later life — a reminder that rare diseases often carry answers far larger than the questions that first prompted them.
Three decades ago, Richard Sifers noticed something that didn't add up. Some people carrying a genetic mutation in the alpha1-antitrypsin gene developed severe liver disease as infants and needed transplants to survive. Others with the same mutation didn't get sick until late in life, if at all. The variation was stark enough to demand explanation, and Sifers, a pathologist at Baylor College of Medicine, decided to chase it.
Alpha1-antitrypsin, or AAT, is a protein the liver manufactures and sends into the bloodstream to protect the lungs from damage. A mutation called Z produces a defective version that cannot fold properly into its three-dimensional shape. Trapped in the liver, unable to reach the lungs, the misfolded protein accumulates like trash in a room with no exit. About one in 1,700 people carry two copies of the Z mutation, but only 17 percent of those newborns develop clinically significant liver disease, and fewer than 3 percent progress to life-threatening failure as infants. The question haunted Sifers: why did some babies sicken while others did not?
His first major contribution was developing a screening test to identify which newborns faced the highest risk. But the test revealed a frustrating gap in his knowledge. He could predict who would get sick, but not why. As he studied the disease more closely, he noticed that the defective AAT-Z protein was piling up inside liver cells instead of being cleared away. This suggested the cell's natural disposal system was failing. Sifers and his colleagues began mapping how cells actually get rid of misfolded proteins. They discovered a process: defective proteins are shuttled from the endoplasmic reticulum, where they are made, to the cytosol, where they are broken down in structures called proteasomes. The key was tagging them for destruction. Sifers found that an enzyme called Man1b1 acted as a quality-control inspector, removing sugar molecules called mannose from the misfolded proteins and marking them for degradation.
In 2009, Sifers's team studied liver tissue from infants and young children who had undergone transplantation for end-stage disease. They also conducted genetic analysis and laboratory experiments. What they found was a genetic variant—a single nucleotide polymorphism—that reduced the expression of the Man1b1 gene. Infants carrying both the AAT-Z mutation and this variant had lower levels of Man1b1 protein in their liver cells. With less of the cleanup enzyme available, their livers could not handle the accumulation of misfolded protein. The threshold for damage was reached faster, triggering liver failure in infancy. After years of investigation, Sifers had solved the mystery.
But the work took an unexpected turn. As Sifers and his colleagues continued studying Man1b1, they discovered the enzyme had a second job nobody had described before. Beyond its role in removing mannose and tagging proteins for destruction, Man1b1 appeared to promote protein degradation through an entirely separate mechanism. The conventional system operates on one side of the enzyme, the C-terminal domain. The new system works from the other side, the N-terminal domain. The researchers propose that this unconventional pathway may eliminate soluble protein aggregates linked to conformational diseases—conditions where proteins misfold and accumulate, including Alzheimer's disease, intellectual disability disorders, and even HIV infection.
The implications ripple outward. Man1b1 has already been connected to multiple congenital disorders and poor outcomes in bladder cancer patients. By studying a rare disease affecting infants, Sifers's team had uncovered a cellular mechanism that might apply to far more common conditions. The work demonstrates a principle that guides much of medical research: rare diseases often illuminate fundamental biology. A pathway discovered in the livers of sick babies could eventually point toward treatments for neurological disorders that emerge decades later in life. The question now is not why the research matters, but how quickly it can be translated into therapies.
Citações Notáveis
I could tell whether a child was at high risk of having liver disease, but still did not know what was causing the condition.— Dr. Richard Sifers, describing the gap in his understanding after developing the screening test
By investigating a rare liver disease in babies, we have stumbled upon a pathway that could possibly be targeted to prevent more common neurological disorders occurring in late age.— Dr. Richard Sifers, on the broader implications of the research
Quer a matéria completa?
Leia o original em News-Medical.net ↗
Health & Medicine